Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.

Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. These dynamics have converged to create attractive opportunities for the development of precision therapies.

At Chinook, we are focused on rare, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program, atrasentan, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned initiation of a phase 1 clinical trial in healthy volunteers in the first half of 2022. In addition, we are conducting research programs in other rare, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways.

Our Purpose & Values

We discover and develop precision therapies to preserve kidney function and make dialysis and transplant unnecessary for people living with kidney disease.


Chinook Values graphic


Eric Dobmeier photo

Eric Dobmeier
President and Chief Executive Officer

Eric Bjerkholt photo

Eric Bjerkholt
Chief Financial Officer

Tom Frohlich photo

Tom Frohlich
Chief operating Officer

Delphine Imbert photo

Delphine Imbert, PhD

Jodi Jamieson photo

Jodi Jamieson
Vice President, Human Resources

charlotte jones burton photo

Charlotte Jones-Burton, MD, MS
Senior Vice President, Product Development and Strategy

Andrew King photo

Andrew King, DVM, PhD
chief scientific officer

Renata Oballa photo

Renata Oballa, PhD
Vice President, Research Operations and Vancouver Site Head

Kirk Shumacher photo

Kirk Schumacher, JD
Senior Vice President AND GENERAL COUNSEL

Board of Directors

Eric Dobmeier photo

Eric Dobmeier
President and CEO

srini akkaraju photo

Srini Akkaraju

jerel davis photo

Jerel Davis
Lead Director

michelle griffin photo

Michelle Griffin

ross haghighat photo

Ross Haghighat

mahesh krishnan photo

Mahesh Krishnan

dolca thomas photo

Dolca Thomas